BellRing Brands (BRBR)
(Delayed Data from NYSE)
$57.24 USD
-0.44 (-0.76%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $57.24 0.00 (0.00%) 6:02 PM ET
3-Hold of 5 3
C Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.24 USD
-0.44 (-0.76%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $57.24 0.00 (0.00%) 6:02 PM ET
3-Hold of 5 3
C Value A Growth D Momentum A VGM
Zacks News
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
High labor costs and inflationary pressures are likely to have weighed on DaVita's (DVA) first-quarter top line.
Analysts Estimate National Vision (EYE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BellRing Brands Inc. (BRBR) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
BellRing Brands (BRBR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Can Cigna's (CI) Q1 Earnings Beat on Medical Customers Growth?
by Zacks Equity Research
The first-quarter results of Cigna (CI) are likely to reflect an expanding customer base and growth in specialty pharmacy services.
BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q2 sales.
What Awaits Lantheus Holdings (LNTH) This Earnings Season?
by Zacks Equity Research
Lantheus Holdings' (LNTH) first-quarter results are likely to reflect solid top-line results on the back of robust product adoption.
BellRing Brands (BRBR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
BellRing Brands (BRBR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BellRing Brands (BRBR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
BellRing Brands (BRBR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will BellRing Brands (BRBR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
BellRing Brands (BRBR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BellRing Brands (BRBR) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 22.22% and 6.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Envista (NVST) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BellRing Brands (BRBR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
BellRing Brands (BRBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why BellRing Brands (BRBR) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
BellRing Brands (BRBR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
OrganiGram (OGI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 1.43%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for BellRing Brands (BRBR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to BellRing Brands (BRBR) stock based on the movements in the options market lately.
BellRing Brands (BRBR) Beats Q4 Earnings Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 6.90% and 6.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
PLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 15.91% and 35.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
BellRing Brands (BRBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lantheus Holdings (LNTH) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 19.28% and 4.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for BellRing Brands (BRBR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to BellRing Brands (BRBR) stock based on the movements in the options market lately.
Do Options Traders Know Something About BellRing Brands (BRBR) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to BellRing Brands (BRBR) stock based on the movements in the options market lately.
BellRing Brands (BRBR) Beats Q3 Earnings Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 3.33% and 4.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Vapotherm (VAPO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vapotherm (VAPO) delivered earnings and revenue surprises of -7.69% and 32.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in BellRing Brands (BRBR) Stock?
by Zacks Equity Research
Investors need to pay close attention to BellRing Brands (BRBR) stock based on the movements in the options market lately.
Implied Volatility Surging for BellRing Brands (BRBR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to BellRing Brands (BRBR) stock based on the movements in the options market lately.